Fig. 3From: Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV studySubgroup analyses of overall survival according to initial dose (A) and daily exposure (B) of apatinib and progression-free survival according to initial dose (C) and daily exposure (D) of apatinibBack to article page